CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1467-1472

  Sibin, M K ^a   Bhat, Dhananjaya I ^a   Lavanya, Ch ^a   Jeru Manoj, M ^a   Aakershita, S ^a   Chetan, G K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

CDKN2A; Deletion; Exon 2; Glioma; Mutations; P16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; METHIONINE; PROTEIN P16; VALINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CODON; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; INDIAN; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; OLIGODENDROGLIOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; CHILD; CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXONS; FEMALE; GLIOMA; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE DELETION;

EID: 84898857554     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1201-5     Document Type: Article

References (35)

1. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205(12):613-21.
2. Kita D, Yonekawa Y, Weller M, Ohgaki H. PI3KCA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl). 2007;113:295-302. (Pubitemid 46443564)
3. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217-24. (Pubitemid 26246377)
4. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994;8(1):23-6.
5. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-6. (Pubitemid 24153417)
6. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92(6):713-23. (Pubitemid 28155311)
7. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993-1000. (Pubitemid 26006540)
8. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosom Cancer. 1996;15(2):77-88.
9. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, et al. Mutations of the p16 gene in gliomas. Oncogene. 1996;12(1):63-7. (Pubitemid 26041241)
10. Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene. 1995;11(3): 597-600.
11. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994;54(24):6353-8.
12. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer. 1997;75(1):2-8. (Pubitemid 27007266)
13. Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M. MTS1/p16/CDKN2 lesions in primary glioblastomamultiforme. Am J Pathol. 1995;146(3):613-9.
14. Biernat W,Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 1997;94:303-9. (Pubitemid 27450108)
15. Barker FG, Chen P, Furman F, Aldape KD, Edwards MS, Israel MA. P16 deletion and mutation analysis in human brain tumors. J Neurooncol. 1997;31:17-23. (Pubitemid 27077705)
16. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. JNeurooncol. 1999;41(3):205-11. (Pubitemid 29209808)
17. Riese U, Dahse R, Fiedler W, Theuer C, Koscielny S, Ernst G, et al. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Mol Med. 1999;4:6.
18. Hamzeiy H. Non-radioactive single-strand conformation polymorphis (SSCP) analysis of relatively long PCR products. RPS. 2006;1:8-14.
19. Brant J. Bassam, Gustavo Caetano-Anollés, Silver staining of DNA in polyacrylamide gels. Appl Biochem Biotechnol. 1993;42(2-3):181-8.
20. Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 1995;55(21):4818-23.
21. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725-34. (Pubitemid 28155312)
22. Perry A, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, et al. Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol. 1997;56:999-1008. (Pubitemid 27386129)
23. Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:984-8.
24. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res. 1994;54:6338-9.
25. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of themultiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res. 1995;55:20-3.
26. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 1996;56:150-3. (Pubitemid 26010393)
27. Mochizuki S, Iwadate Y, Namba H, Yoshida Y, Yamaura A, Sakiyama S, et al. Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients. Int J Oncol. 1999;15:983-9.
28. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, et al. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol. 1996;55:1026-31. (Pubitemid 26338014)
29. Sonoda Y, Yoshimoto T, Sekiya T. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene. 1995;11:2145-9.
30. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer. 1996;78:287-93. (Pubitemid 26234572)
31. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M, et al. Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastomamultiforme. J Neurosurg. 2002;96(5):815-22. (Pubitemid 34415394)
32. Purkait S, Jha P, Sharma MC, Suri V, Sharma M, Kale SS, et al. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology. 2013;33(4):405-12.
33. Sailasree R, Abhilash A, Sathyan KM, Nalinakumari KR, Thomas S, Kannan S. Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. CancerEpidemiol Biomarkers Prev. 2008;17(2):414-20. (Pubitemid 351272795)
34. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994;265(5170):415-7. (Pubitemid 24259979)
35. Kukita Y, Higasa K, Baba S, Nakamura M, Manago S, Suzuki A, et al. Single-strand conformation polymorphism. In: Cotton RGH, Edkins E, Forrest S, editors.Mutation detection, a practical approach. Oxford: IRL Press; 1998. p. 2259-66.